Abstract
Life expectancy has impressively increased over the past century and the US population over 65 years is rapidly growing, especially those over 80 years. In fact, persons older than 80 years have increased by more than 250% between the years 1960 and 2000, and it is expected that the population aged >75 years will triple by the year 2030. With the increase of the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients needs special attention because older patients usually suffered of several co-morbidities and their management represents a challenge for physicians. In fact, older patients treated for lymphoma may not tolerate the high-dose therapies used in younger patients and have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities. The widespread use of a comprehensive geriatric assessment tool might overcome the difficulty to run prospective clinical trial in elderly patients with lymphoma.
Keywords: Elderly patients, lymphoma, comprehensive geriatric assessment, therapy related toxicity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Volume: 13 Issue: 9
Author(s): Rosanna Ciancia, Umberto Tirelli, Josep-Maria Ribera and Michele Spina
Affiliation:
Keywords: Elderly patients, lymphoma, comprehensive geriatric assessment, therapy related toxicity.
Abstract: Life expectancy has impressively increased over the past century and the US population over 65 years is rapidly growing, especially those over 80 years. In fact, persons older than 80 years have increased by more than 250% between the years 1960 and 2000, and it is expected that the population aged >75 years will triple by the year 2030. With the increase of the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients needs special attention because older patients usually suffered of several co-morbidities and their management represents a challenge for physicians. In fact, older patients treated for lymphoma may not tolerate the high-dose therapies used in younger patients and have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities. The widespread use of a comprehensive geriatric assessment tool might overcome the difficulty to run prospective clinical trial in elderly patients with lymphoma.
Export Options
About this article
Cite this article as:
Ciancia Rosanna, Tirelli Umberto, Ribera Josep-Maria and Spina Michele, Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660363
DOI https://dx.doi.org/10.2174/18715206113136660363 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Conformational Restriction in Medicinal Chemistry
Current Topics in Medicinal Chemistry MDR Reversal by Deprenylated Tetracyclic and Hexacyclic Analogues of N-Acetylardeemin: Confirmation of the Ardeemin Pharmacophore
Letters in Drug Design & Discovery Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3Kα Enzyme
Anti-Cancer Agents in Medicinal Chemistry Biologic Agents for Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis and Biological Activity of Quinoxalone Derivatives as BRD4 Bromodomain Inhibitors
Letters in Drug Design & Discovery Chemical Diversity and Bioactivity of Marine Sponges of the Genus Oceanapia: A Review
Mini-Reviews in Organic Chemistry The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Kinase Inhibitor Conjugates
Current Pharmaceutical Design Recent Advances in Radiopharmaceutical Application of Matched-Pair Radiometals
Current Topics in Medicinal Chemistry The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Interactions of Phenothiazines with Lipid Bilayer and their Role in Multidrug Resistance Reversal
Current Drug Targets 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways
Current Neurovascular Research Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Redox-Sensitive Smart Nanosystems for Drug and Gene Delivery
Current Organic Chemistry Targeting Leukocytes in Immune Glomerular Diseases
Current Medicinal Chemistry